WO1990000594A3 - Recombinant mycobacterial expression vehicles and uses therefor - Google Patents

Recombinant mycobacterial expression vehicles and uses therefor Download PDF

Info

Publication number
WO1990000594A3
WO1990000594A3 PCT/US1989/002962 US8902962W WO9000594A3 WO 1990000594 A3 WO1990000594 A3 WO 1990000594A3 US 8902962 W US8902962 W US 8902962W WO 9000594 A3 WO9000594 A3 WO 9000594A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacteria
recombinant
dna
interest
coli
Prior art date
Application number
PCT/US1989/002962
Other languages
French (fr)
Other versions
WO1990000594A2 (en
Inventor
Barry R Bloom
Ronald W Davis
William R Jacobs Jr
Richard A Young
Robert N Husson
Original Assignee
Whitehead Biomedical Inst
Einstein Coll Med
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Einstein Coll Med, Univ Leland Stanford Junior filed Critical Whitehead Biomedical Inst
Priority to EP89908028A priority Critical patent/EP0424437B1/en
Priority to DE68929507T priority patent/DE68929507T2/en
Priority to AT89908028T priority patent/ATE256730T1/en
Publication of WO1990000594A2 publication Critical patent/WO1990000594A2/en
Publication of WO1990000594A3 publication Critical patent/WO1990000594A3/en
Priority to US08/095,734 priority patent/US5807723A/en
Priority to US08/096,027 priority patent/US5591632A/en
Priority to US08/444,623 priority patent/US5866403A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Recombinant cultivable mycobacteria capable of expressing DNA of interest which encodes at least one protein antigen against which an immune response is desired and methods of introducing DNA of interest into mycobacteria. In the recombinant mycobacteria, the DNA of interest is stably maintained extrachromosomally or is stably integrated into genomic DNA. Such recombinant mycobacteria are useful as vehicles to be used as vaccines to provide immunity against a pathogen, as anti-fertility ''vaccines'' and as a means to nonspecifically augment immune responses to foreign antigens expressed by BCG or to treat human cancers. The present invention also relates to recombinant vectors useful in introducing DNA of interest into mycobacteria, where it is expressed. One type of vector is a recombinant plasmid capable of replicating as a plasmid in E. coli and of lyzogenizing a mycobacterial host. A second type of vector is a recombinant plasmid which can be introduced into mycobacteria, where it is stably maintained extrachromosomally. A third type of recombinant vector is one which replicates in E. coli but not in mycobacteria. It includes: 1) a mycobacterial gene, or portions thereof, necessary for recombination with homologous sequences in the genome of mycobacteria transformed with the recombinant plasmid; 2) all or a portion of a gene which encodes a polypeptide or protein whose expression is desired in mycobacteria transformed with the recombinant plasmid; 3) DNA sequences necessary for replication and selection in E. coli; and 4) DNA sequences necessary for selection in mycobacteria (e.g., drug resistance).
PCT/US1989/002962 1987-03-02 1989-07-07 Recombinant mycobacterial expression vehicles and uses therefor WO1990000594A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP89908028A EP0424437B1 (en) 1988-07-07 1989-07-07 Recombinant mycobacterial expression vehicles and uses therefor
DE68929507T DE68929507T2 (en) 1988-07-07 1989-07-07 RECOMBINANT MYCOBACTERIAL EXPRESSION CARRIERS AND THEIR USE
AT89908028T ATE256730T1 (en) 1988-07-07 1989-07-07 RECOMBINANT MYCOBACTERIAL EXPRESSION CARRIERS AND USE THEREOF
US08/095,734 US5807723A (en) 1987-03-02 1993-07-22 Homologously recombinant slow growing mycobacteria and uses therefor
US08/096,027 US5591632A (en) 1987-03-02 1993-07-22 Recombinant BCG
US08/444,623 US5866403A (en) 1987-03-02 1995-05-19 Homologously recombinant slow growing mycobacteria and uses therefor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21639088A 1988-07-07 1988-07-07
US216,390 1988-07-07
US22308988A 1988-07-22 1988-07-22
US223,089 1988-07-22
US07/361,944 US5504005A (en) 1987-03-02 1989-06-05 Recombinant mycobacterial vaccine
US361,944 1989-06-05

Publications (2)

Publication Number Publication Date
WO1990000594A2 WO1990000594A2 (en) 1990-01-25
WO1990000594A3 true WO1990000594A3 (en) 1990-05-03

Family

ID=27396269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/002962 WO1990000594A2 (en) 1987-03-02 1989-07-07 Recombinant mycobacterial expression vehicles and uses therefor

Country Status (8)

Country Link
US (5) US5504005A (en)
EP (1) EP0424437B1 (en)
JP (2) JP3485916B2 (en)
AT (1) ATE256730T1 (en)
AU (1) AU3867789A (en)
CA (1) CA1339526C (en)
DE (1) DE68929507T2 (en)
WO (1) WO1990000594A2 (en)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
EP0400973B1 (en) * 1989-05-31 1996-07-31 Ajinomoto Co., Inc. Mycobacterial secretory expression vectors and transformants
JP2903414B2 (en) * 1989-05-31 1999-06-07 味の素株式会社 Acid-fast bacterium secretion expression vector and acid-fast bacterium
EP0478664B1 (en) * 1989-06-19 2003-09-17 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
WO1991013157A1 (en) * 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
CA2045842A1 (en) * 1990-07-16 1992-01-17 William R. Jacobs Dna capable of site-specific integration into mycobacteria
GB9015888D0 (en) * 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5637303A (en) * 1990-10-25 1997-06-10 Commonwealth Scientific And Industrial Research Organisation Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination
CA2094718A1 (en) * 1990-10-25 1992-04-26 Anthony J. Radford Corynebacteria and related organisms as vaccine vectors
AU643842B2 (en) * 1990-10-25 1993-11-25 Commonwealth Scientific And Industrial Research Organisation Corynebacteria and related organisms as vaccine vectors
CA2110682A1 (en) * 1991-06-06 1992-12-10 Charles K. Stover Induction of ctl responses to foreign antigens expressed in mycobacteria
EP0587765A4 (en) * 1991-06-06 1994-11-02 Medimmune Inc Induction of immune response against tetanus toxin through administration of mycobacteria expressing tetanus toxin or fragments.
US6566121B1 (en) 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
JPH06511145A (en) * 1991-06-13 1994-12-15 アルバート　アインシュタイン　カレッジ　オブ　メディシン、ア　ディビジョン　オブ　イェシーバ　ユニバーシティ Insertional mutations within mycobacteria
EP0521220A1 (en) * 1991-06-14 1993-01-07 Institut Pasteur Recombinant immunogenic actinomycetale
US5750384A (en) * 1992-02-07 1998-05-12 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University L5 shuttle phasmids
US6300061B1 (en) 1992-02-07 2001-10-09 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial species-specific reporter mycobacteriophages
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
PT700445E (en) 1993-06-04 2002-07-31 Whitehead Biomedical Inst STRESS PROTEINS AND THEIR USES
AU1097795A (en) 1993-11-23 1995-06-13 Regents Of The University Of California, The Abundant extracellular products and methods for their production and use
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
FR2720076B1 (en) 1994-05-20 1996-08-02 Inst Nat Sante Rech Med Shuttle vectors for the introduction of DNA into mycobacteria and use of these bacteria as vaccines.
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU774535B2 (en) * 1995-10-20 2004-07-01 Actogenix Nv Delivery of biologically active polypeptides
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
DE69838948T2 (en) * 1997-01-21 2008-10-02 The Regents Of The University Of California, Oakland EPITOPES OF EXTRACELLULAR ANTIGEN
EP1047451A1 (en) * 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
KR100843109B1 (en) 1997-08-05 2008-07-02 엔벤타 바이오파마슈티컬스 코포레이션 Immune responses against HPVhuman papillomavirus antigens elicited by compositions comprising a fusion protein comprising an HPV antigen and a stress protein
AU3710597A (en) * 1997-08-06 1999-03-01 Laboratorio Medinfar-Produtos Farmaceuticos, Lda Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system
US6322991B1 (en) * 1997-08-21 2001-11-27 York University High-throughput screens for enzyme inhibitors
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US5972700A (en) * 1997-09-26 1999-10-26 Albert Einstein College Of Medicine Of Yeshiva University TM4 conditional shuttle phasmids and uses thereof
US6387694B1 (en) * 1998-04-03 2002-05-14 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial isocitrate lyase gene and uses thereof
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
EP1105490A1 (en) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU3593200A (en) * 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6495347B1 (en) 1999-07-08 2002-12-17 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
AU1814101A (en) 2000-01-14 2001-07-24 Massachusetts Institute Of Technology In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete ATP binding domain and is CD4+ cell-independent
US6471967B1 (en) 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
ATE346925T1 (en) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd IMMUNOGENIC POLYPEPTIDES ENCODED BY MAGE MINIGENE AND USES THEREOF
AU6867801A (en) * 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
AU2001285633A1 (en) 2000-08-25 2002-03-04 Aventis Pasteur Limited Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
AU2002211201B2 (en) 2000-11-02 2007-05-31 The National University Of Singapore aopB Gene, protein, homologs, fragments and variants thereof, and their use for cell surface display
CN1264572C (en) 2001-02-05 2006-07-19 斯特雷斯根生物技术公司 Hepatitis B virus treatment
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US7758874B2 (en) * 2002-02-19 2010-07-20 Albert Einstein College Of Medicine Of Yeshiva University Attenuated Mycobacterium tuberculosis vaccines
AU2003209345A1 (en) * 2002-02-19 2003-09-09 Albert Einstein College Of Medicine Of Yeshiva University Attenuated mycobacterium tuberculosis vaccines
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
ATE517122T1 (en) 2002-04-09 2011-08-15 Sanofi Pasteur Ltd MODIFIED CEA NUCLEIC ACID AND CORRESPONDING EXPRESSION VECTORS
WO2004001020A2 (en) * 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and means to promote gut absorption
EP1535627B1 (en) * 2002-08-16 2008-07-09 Japan Science and Technology Agency Recombinant bcg vaccine
WO2004046346A2 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain
ES2347239T3 (en) * 2002-12-02 2010-10-27 Amgen Fremont Inc. ANTIBODIES DIRECTED TO THE TUMOR NECROSIS FACTOR AND USES OF THE SAME.
WO2004066928A2 (en) * 2003-01-24 2004-08-12 Albert Einstein College Of Medicine Of Yeshiva University Use of mycobacterial vaccines in cd4+ or cd8+ lymphocyte-deficient mammals
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
DK2206514T3 (en) 2003-10-16 2014-04-22 Univ California Recombinant intracellular pathogenic immunogenic compositions and methods of use
US8383132B2 (en) * 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US8287879B2 (en) * 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US8163294B2 (en) * 2003-10-16 2012-04-24 The Regents Of The University Of California Growth regulatable recombinant BCG compositions
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20060002956A1 (en) * 2004-04-05 2006-01-05 Surber Mark W Minicells as vaccines
AU2006204907B2 (en) * 2005-01-12 2011-08-11 Albert Einstein College Of Medicine, Inc. Mycobacterial mutants affecting host apoptosis
WO2006076343A1 (en) * 2005-01-12 2006-07-20 Albert Einstein College Of Medicine Of Yeshiva University Mycobacteria expressing hiv-1 and malaria antigens
EP1841860A2 (en) 2005-01-18 2007-10-10 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Mycobacteria with mannose cap-deficient lipoarabinomannan
JP2009502747A (en) * 2005-07-14 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア Bactericidal mixtures based on 1-methyl-pyrazol-4-ylcarboxyanilides
ES2596855T3 (en) 2005-11-29 2017-01-12 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
US8168421B2 (en) * 2005-12-09 2012-05-01 University Of Georgia Research Foundation, Inc. Microbial vaccine and vaccine vector
WO2007084353A2 (en) * 2006-01-12 2007-07-26 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial seca2 mutants
DK2774621T3 (en) 2007-01-25 2018-05-07 Intrexon Actobiotics Nv TREATMENT OF IMMUNE DISEASE BY MUCOSAL ADMINISTRATION OF ANTIGENS
US8591918B2 (en) 2007-03-19 2013-11-26 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial mutants inducing IL-12
CA2684923C (en) 2007-05-02 2015-01-06 Merial Limited Dna plasmids having improved expression and stability
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
KR101741426B1 (en) 2008-12-24 2017-05-30 더 킹덤 오드 더 네덜란드, 레프리젠티드 바이 더 미니스트리 오브 헬스, 웰페어 앤드 스포츠, 온 비하프 오브 더 미니스터, 더 내셔널 인스티튜트 포 퍼블릭 헬스 앤드 디 인바이런먼트 Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
EA026228B1 (en) 2011-08-08 2017-03-31 Кьюэлаб Онколоджи, Инк. METHODS AND COMPOSITIONS RELATING TO p62 FOR THE TREATMENT AND PROPHYLAXIS OF CANCER
US9447449B2 (en) 2011-10-21 2016-09-20 Albert Einstein College Of Medicine, Inc. Recombinant mycobacteriophages for delivery of nucleic acids of interest into mycobacteria
BR102012003790A2 (en) 2012-02-17 2014-04-22 Fundacao Butantan RECOMBINANT MYCOBACTERIUM CEPA, IMMUNOGENIC COMPOSITION AND USE
US20150211012A1 (en) 2012-08-31 2015-07-30 Laboratorios Del Dr. Esteve S.A. Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine
EP2895501B1 (en) 2012-09-17 2017-01-18 Novartis Tiergesundheit AG Salmonid alphavirus and uses thereof
ES2642879T3 (en) 2012-11-02 2017-11-20 Novartis Tiergesundheit Ag Flavivirus associated with Theiler's disease
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
EP3089753B8 (en) 2013-12-29 2020-10-28 Curelab Oncology, Inc. Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
ES2847311T3 (en) 2014-08-05 2021-08-02 MabQuest SA Immunological reagents that bind to PD-1
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents
EP3405497A2 (en) 2016-01-22 2018-11-28 Mabquest SA Immunological reagents
EP3436603A1 (en) * 2016-03-31 2019-02-06 University Of The Witwatersrand, Johannesburg Genetically modified strains of mycobacterium smegmatis
JP2019520075A (en) * 2016-06-30 2019-07-18 テクノロジー イノベーション モメンタム ファンド（イスラエル）リミテッド パートナーシップＴｅｃｈｎｏｌｏｇｙ Ｉｎｎｏｖａｔｉｏｎ Ｍｏｍｅｎｔｕｍ Ｆｕｎｄ（ｉｓｒａｅｌ）Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ Bacteriophage variants having a broad host range, methods of preparation and use thereof in transducing a nucleic acid into a host of interest
EP3596202A4 (en) 2017-03-14 2021-01-27 The Regents of the University of California Genome-wide identification of immune evasion functions in a virus
CN109825497A (en) * 2019-01-25 2019-05-31 石河子大学 A kind of preparation method and applications of novel tubercle bacillus fusant bacterial strain
WO2021009697A2 (en) 2019-07-15 2021-01-21 Lausanne University Hospital Hiv binding agents
TW202206098A (en) 2020-08-11 2022-02-16 美商碩騰服務公司 Anti-coronavirus vaccines
CN114315985A (en) 2020-09-29 2022-04-12 硕腾服务有限责任公司 Attenuated porcine epidemic diarrhea virus
CA3230802A1 (en) 2021-08-31 2023-03-09 Zoetis Services Llc Attenuated alphavirus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127328A2 (en) * 1983-04-28 1984-12-05 Genex Corporation The use of chromosomal integration to stabilize heterologous genes
EP0191643A2 (en) * 1985-02-13 1986-08-20 Biotechnica International, Inc. Integration of a gene into a chromosome and controllable excision therefrom
WO1988000974A2 (en) * 1986-07-31 1988-02-11 Whitehead Institute For Biomedical Research Genes encoding antigens of m. leprae
WO1988006626A1 (en) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127328A2 (en) * 1983-04-28 1984-12-05 Genex Corporation The use of chromosomal integration to stabilize heterologous genes
EP0191643A2 (en) * 1985-02-13 1986-08-20 Biotechnica International, Inc. Integration of a gene into a chromosome and controllable excision therefrom
WO1988000974A2 (en) * 1986-07-31 1988-02-11 Whitehead Institute For Biomedical Research Genes encoding antigens of m. leprae
WO1988006626A1 (en) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTACTS, Vol. 96, No. 19, 10 May 1982, (Columbus, Ohio, US), S. BRENNER et al.: "Phasmids: Hybrids Between Co1E1 Plasmids and E. Coli Bacteriophage Lambda", page 187* Abstact No. 156476C, & Gene 1982, 17(1), 27-44* *
Infection and Immunity, Vol. 52, No. 1, April 1986, American Society for Microbiology, W.R. JACOBS et al.: "in Vivo Repack-Aging of Recombinant Cosmid Molecules for Analyses of Salmonella Typhimurium, Streptococcus Mutants, and Mycobacterial Genomic Libraries", pages 101-109 *
Nature, Vol. 327, No. 6122, 11-17 June 1987, (Basingstoke, Hampshire, GB), W.R. Jacobs, Jr. et al.: "Introduction of Foreign DNA into Mycobacteria Using a Shuttle Phasmid", pages 532-535 *
Proc. Natl. Acac. Sci. USA, Vol. 85, September 1988, S.B. SNAPPER et al.: "Lysogeny and Transformation in Mycobacteria: Stable Expression of Foreign Genes", pages 6987-6991, *
Reviews of Infectious Diseases, Vol. II, Supplement 2, March-April 1989, The University of Chicago, W.R. JACOBS, JR. et al.: "Mycobacteriophage Vector Systems", pages 404-410 *

Also Published As

Publication number Publication date
JP3485916B2 (en) 2004-01-13
AU3867789A (en) 1990-02-05
US5504005A (en) 1996-04-02
WO1990000594A2 (en) 1990-01-25
US5968733A (en) 1999-10-19
ATE256730T1 (en) 2004-01-15
CA1339526C (en) 1997-11-04
US6270776B1 (en) 2001-08-07
EP0424437B1 (en) 2003-12-17
JP2000350578A (en) 2000-12-19
US6372478B1 (en) 2002-04-16
DE68929507D1 (en) 2004-01-29
US5854055A (en) 1998-12-29
JPH04500305A (en) 1992-01-23
EP0424437A1 (en) 1991-05-02
DE68929507T2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
WO1990000594A3 (en) Recombinant mycobacterial expression vehicles and uses therefor
DE3854840D1 (en) RECOMBINANT MYCOBACTERIAL VACCINE
AU5848090A (en) Vector-mediated genomic insertion and expression of dna in bcg
WO1996040915A3 (en) Novel ctla4/cd28 ligands and uses therefor
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
JP2001514000A5 (en)
WO2001096392A3 (en) 22109, a novel human thioredoxin family member and uses thereof
WO2002008258A3 (en) 65494, a human g-protein-coupled receptor family member and uses thereof
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
WO2002018556A3 (en) 8797, a human galactosyltransferase and uses thereof
WO2001096400A3 (en) 52871, a novel human g protein coupled receptor and uses thereof
WO2001066764A3 (en) 16835, a human phospholipase c and uses thereof
WO2002024743A3 (en) 55063, a human nmda family member and uses thereof
WO2001077329A3 (en) Human twik molecules and uses thereof
WO2002020801A3 (en) 26199, 33530, 33949, 47148, 50226, and 58764, human transferase family members and uses therefor
WO2002006326A3 (en) 62088, a human nucleoside phosphatase family member and uses thereof
WO2002059314A3 (en) A human melanoma associated antigen and uses therefor
WO2002002761A3 (en) 57658, a human uridine kinase and uses thereof
AU2002359572A1 (en) 15603, a human ion channel family member
WO2001081586A3 (en) 21657, a human short-chain dehydrogenase and uses thereof
WO2003002720A3 (en) 2150, a human protein kinase family member and uses therefor
WO2002026983A3 (en) 56115, a novel human twik potassium channel and uses therefor
WO2002024911A3 (en) 63760, a novel human transporter and uses thereof
WO2003037931A3 (en) Human angiomotin-like protein 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR DK FI HU JP NO RO SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR DK FI HU JP NO RO SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989908028

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989908028

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989908028

Country of ref document: EP